For Diag2Tec, collaborate with our partners
to shape the future in medical is important to us
Today, with our services and proprietary models, our expertise in Hematological Cancers and our technologies, we contribute with you for a best medical future.
Diag2Tec is interested in hearing from qualified companies able to partner with us to further develop services and R&D projects around Hematological cancers, on a mutually beneficial basis.
International network of academic, clinical and industrial collaborators
The establishment of a network of agreements and collaborations with academic laboratories, clinical centres and industrial leaders is at the centre of Diag2Tec’s strategy. We are constantly looking for new propositions for collaboration in the field of hematological cancers.
Since the begining of the Diag2Tec history, we have collaborated with leading academic teams in the field of the hematology cancers notably the INSERM ( French National Institute of Health and Medical Research), and CNRS ( French National Centre for Scientific Research) teams; the Regional University Hospital Centre of Montpellier (CHRU), in France. The Company has demonstrated its commitment to collaborative projects, as is shown today by its services and by its biomarker pipeline, resulting from rich academic collaborations.
Diag2Tec is also collaborating with a world leading cancer centre (CHRU Montpellier) with the clinic hematological service. Our objectives is to expand this type of collaboration with a fruitful partnership with other clinical centres leader in Multiple Myeloma.
LET’S WORK TOGETHER
So contact us, today, if you think you have what it takes to partner with Diag2Tec and together we will be more strong